Clinical trial results:
A Phase 2 study to investigate the efficacy, safety, and tolerability of six weeks treatment with V565 in subjects with active Crohn's disease.

Summary

EudraCT number	2016-002939-15
Trial protocol	CZ DE AT HU SK NL NO GB
Global end of trial date	08 March 2019

Results information

Result version number	v1 (current)
This version publication date	12 November 2021
First version publication date	12 November 2021

Trial information

Trial identification

Sponsor protocol code	V56502

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02976129
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	VHsquared
Sponsor organisation address	1 Lower Court, Cambridge, United Kingdom, CB22 3GN
Public contact	Clinical Trial Information Desk, VHsquared Ltd, 0044 1223837650, info@vhsquared.com
Scientific contact	Clinical Trial Information Desk, VHsquared Ltd, 0044 1223837650, info@vhsquared.com

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	08 March 2019
Is this the analysis of the primary completion data?	Yes
Primary completion date	08 March 2019
Global end of trial reached?	Yes
Global end of trial date	08 March 2019
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To investigate the efficacy, safety and tolerability of 6 weeks treatment with V565 in subjects with active Crohn's Disease.

Protection of trial subjects:

The study protocol, all study protocol amendments, written study subject information, informed consent form (ICF), Investigator’s Brochure and any other relevant documents were reviewed and approved by an Independent Ethics Committee (IEC) and Institutional Review Board (IRB) at each study site.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	15 February 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	United Kingdom: 9
Country: Number of subjects enrolled	Canada: 2
Country: Number of subjects enrolled	United States: 7
Country: Number of subjects enrolled	Ukraine: 34
Country: Number of subjects enrolled	Serbia: 6
Country: Number of subjects enrolled	Norway: 1
Country: Number of subjects enrolled	Netherlands: 1
Country: Number of subjects enrolled	Poland: 14
Country: Number of subjects enrolled	Slovakia: 8
Country: Number of subjects enrolled	Austria: 3
Country: Number of subjects enrolled	Czech Republic: 29
Country: Number of subjects enrolled	Germany: 6
Country: Number of subjects enrolled	Hungary: 5
Worldwide total number of subjects	125
EEA total number of subjects	76

Notes:

Subjects enrolled per age group	
In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	121
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

125 subjects were recruited from 13 countries in North America and Europe.

Pre-assignment

Screening details:

Out of 330 screened subjects, 205 were considered screen failures. A total of 125 subjects were randomised and treated in the study.

Period 1

Period 1 title	Overall trial (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Investigator, Monitor, Data analyst, Subject

Arms

Are arms mutually exclusive?	Yes
Arm title	V565

Arm description:

V565 PO 555mg TID

Arm type	Experimental
Investigational medicinal product name	V565
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

V565 PO 555mg TID

Arm title	Placebo

Arm description:

Placebo PO 3 capsules TID

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

Placebo 3 capsules TID

Number of subjects in period 1	V565	Placebo
Started	82	43
Completed	77	41
Not completed	5	2
Physician decision	-	2
Adverse event, non-fatal	2	-
Missed primary endpoint visit	1	-
Pregnancy	1	-
Lost to follow-up	1	-

Baseline characteristics

Reporting groups	
Reporting group title	V565
Reporting group description: V565 PO 555mg TID	
Reporting group title	Placebo
Reporting group description: Placebo PO 3 capsules TID	

Reporting group values	V565	Placebo	Total
Number of subjects	82	43	125
Age categorical Units: Subjects			
Adults (18-64 years)	78	43	121
From 65-84 years	4	0	4
Age continuous Units: years			
arithmetic mean	37.7	37.2	
standard deviation	± 14.05	± 12.08	-
Gender categorical Units: Subjects			
Female	32	19	51
Male	50	24	74
CDAI score Units: Score on a scale			
arithmetic mean	316.34	296.69	
standard deviation	± 71.283	± 64.344	-
Baseline CRP			
Baseline CRP value for those subjects qualifying for the study based on CRP			
Units: mg/L			
arithmetic mean	21.9	18.7	
standard deviation	± 18.43	± 14.56	-
Baseline FCP			
Baseline FCP for those subjects qualifying for the study on FCP			
Units: µg/g			
arithmetic mean	1082.619	1091.217	
standard deviation	± 804.2154	± 974.0855	-

End points

End points reporting groups	
Reporting group title	V565
Reporting group description: V565 PO 555mg TID	
Reporting group title	Placebo
Reporting group description: Placebo PO 3 capsules TID	

Primary: Proportion of responders at Day 42, defined as subjects achieving both CDAI ≥ 70-point reduction from Baseline or CDAI score < 150, and a reduction of ≥ 40% from the baseline value of CRP or FCP.

End point title	Proportion of responders at Day 42, defined as subjects achieving both CDAI ≥ 70-point reduction from Baseline or CDAI score < 150, and a reduction of ≥ 40% from the baseline value of CRP or FCP.
End point description:	
End point type	Primary
End point timeframe: Day 42	

End point values	V565	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	82	43		
Units: Number of responders	29	16		

Statistical analyses

Statistical analysis title	Statistical analysis
Comparison groups	Placebo v V565
Number of subjects included in analysis	125
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	Regression, Logistic

Secondary: Proportion of subjects achieving a ≥ 100-point reduction in CDAI score and a concomitant reduction of at least 50% in CRP or FCP at Day 42

End point title	Proportion of subjects achieving a ≥ 100-point reduction in CDAI score and a concomitant reduction of at least 50% in CRP

	or FCP at Day 42

End point description:

End point type	Secondary

End point timeframe:

Day 42

End point values	V565	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	82	43		
Units: Number of responders	20	9		

Statistical analyses

Statistical analysis title	Statistical analysis
Comparison groups	V565 v Placebo
Number of subjects included in analysis	125
Analysis specification	Pre-specified
Analysis type	superiority
P-value	> 0.05
Method	Regression, Logistic

Other pre-specified: Proportion of subjects achieving CRP levels within normal limits at Day 14 and 42

End point title	Proportion of subjects achieving CRP levels within normal limits at Day 14 and 42

End point description:

End point type	Other pre-specified

End point timeframe:

Day 14 and 42

End point values	V565	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	31		
Units: Number of patients	11	4		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Proportion of subjects achieving FCP levels within normal limits at Day 14 and 42

End point title	Proportion of subjects achieving FCP levels within normal limits at Day 14 and 42

End point description:

End point type	Other pre-specified

End point timeframe:

Day 14 and 42

End point values	V565	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	23	10		
Units: Number of subjects	7	3		

Statistical analyses

No statistical analyses for this end point

Other pre-specified: Comparative assessment of endoscopic mucosal appearance

End point title	Comparative assessment of endoscopic mucosal appearance

End point description:

Subjects with a pre-treatment endoscopy SES-CD of at least 7 (4 if disease was confined to ileum) had a post-treatment endoscopy to evaluate changes in mucosal appearance. The central reader of the endoscopies, blinded to treatment and sequence, was asked to grade if video A was better or worse than video B. Pre- and post-treatment videos were randomly assigned to A and B. The endpoint is the number of subjects whose post-treatment endoscopy was better than their pre-treatment endoscopy.

End point type	Other pre-specified

End point timeframe:

Day 42

End point values	V565	Placebo		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	32	10		
Units: Proportion of subjects	18	3		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

From first administration of IMP on Day 1 until the follow-up visit 2 weeks after the final dose, at Day 56.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	19.1

Reporting groups

Reporting group title	V565

Reporting group description:

V565 PO 555mg TID

Reporting group title	Placebo

Reporting group description:

Placebo PO 3 capsules TID

Serious adverse events	V565	Placebo	
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 82 (3.66%)	2 / 43 (4.65%)	
number of deaths (all causes)	0	0	
number of deaths resulting from adverse events	0	0	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	1 / 82 (1.22%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 1	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Crohn's disease			
subjects affected / exposed	1 / 82 (1.22%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Vomiting			

subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences causally related to treatment / all	0 / 0	0 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Anal abscess			
subjects affected / exposed	1 / 82 (1.22%)	0 / 43 (0.00%)	
occurrences causally related to treatment / all	0 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 2 %

Non-serious adverse events	V565	Placebo	
Total subjects affected by non-serious adverse events			
subjects affected / exposed	30 / 82 (36.59%)	16 / 43 (37.21%)	
Investigations			
Alanine aminotransferase increased			
subjects affected / exposed	2 / 82 (2.44%)	1 / 43 (2.33%)	
occurrences (all)	2	1	
Aspartate aminotransferase increased			
subjects affected / exposed	2 / 82 (2.44%)	0 / 43 (0.00%)	
occurrences (all)	2	0	
Urine analysis abnormal			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Cardiac disorders			
Tachycardia			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Nervous system disorders			
Headache			
subjects affected / exposed	1 / 82 (1.22%)	1 / 43 (2.33%)	
occurrences (all)	1	1	
Seizure			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Blood and lymphatic system disorders			

Anaemia			
subjects affected / exposed	1 / 82 (1.22%)	1 / 43 (2.33%)	
occurrences (all)	1	1	
Iron deficiency anaemia			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Neutrophilia			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	0	
General disorders and administration site conditions			
Oedema peripheral			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Gastrointestinal disorders			
Abdominal pain			
subjects affected / exposed	4 / 82 (4.88%)	4 / 43 (9.30%)	
occurrences (all)	6	4	
Crohn's disease	Additional description: Three of five cases occurred after end of treatment. One further case was a patient with improvement in lower GI CD, resulting in oesophageal CD becoming the primary problem and therefore an AE		
subjects affected / exposed	5 / 82 (6.10%)	0 / 43 (0.00%)	
occurrences (all)	5	0	
Diarrhoea			
subjects affected / exposed	2 / 82 (2.44%)	2 / 43 (4.65%)	
occurrences (all)	2	2	
Vomiting			
subjects affected / exposed	1 / 82 (1.22%)	2 / 43 (4.65%)	
occurrences (all)	1	2	
Dyspepsia			
subjects affected / exposed	2 / 82 (2.44%)	0 / 43 (0.00%)	
occurrences (all)	2	0	
Nausea			
subjects affected / exposed	2 / 82 (2.44%)	0 / 43 (0.00%)	
occurrences (all)	2	0	
Abdominal distension			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	

Gastrointestinal haemorrhage			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	0	
Gastrooesophageal reflux disease			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Proctalgia			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Respiratory, thoracic and mediastinal disorders			
Cough			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Skin and subcutaneous tissue disorders			
Dry skin			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Psychiatric disorders			
Insomnia			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Personality change			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Renal and urinary disorders			
Pollakiuria			
subjects affected / exposed	1 / 82 (1.22%)	1 / 43 (2.33%)	
occurrences (all)	1	1	
Nephrolithiasis			
subjects affected / exposed	0 / 82 (0.00%)	1 / 43 (2.33%)	
occurrences (all)	0	1	
Infections and infestations			
Anal abscess			
subjects affected / exposed	2 / 82 (2.44%)	0 / 43 (0.00%)	
occurrences (all)	2	0	
Gastroenteritis			

subjects affected / exposed	2 / 82 (2.44%)	0 / 43 (0.00%)	
occurrences (all)	2	0	
Influenza			
subjects affected / exposed	2 / 82 (2.44%)	0 / 43 (0.00%)	
occurrences (all)	3	0	
Pulpitis dental			
subjects affected / exposed	2 / 82 (2.44%)	0 / 43 (0.00%)	
occurrences (all)	2	0	
Metabolism and nutrition disorders			
Hyperglycaemia			
subjects affected / exposed	1 / 82 (1.22%)	1 / 43 (2.33%)	
occurrences (all)	1	1	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported